BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
262 hedge funds and large institutions have $2.73B invested in bluebird bio in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 93 increasing their positions, 86 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
19% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 57
20% less capital invested
Capital invested by funds: $3.41B → $2.73B (-$680M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
262
Holding in Top 10
–
Calls
$45.9M
Puts
$49.1M
Top Buyers
| 1 | +$36.6M | |
| 2 | +$24.6M | |
| 3 | +$18.8M | |
| 4 |
JP Morgan Chase
New York
|
+$18.5M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$18.5M |
Top Sellers
| 1 | -$80.6M | |
| 2 | -$29.6M | |
| 3 | -$26.7M | |
| 4 |
ACA
Anchor Capital Advisors
Boston,
Massachusetts
|
-$21.4M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$19.7M |